Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Merit Medical Systems ( (MMSI) ) is now available.
On January 28, 2025, Merit Medical Systems held a conference call to discuss their WRAPSODY™ Cell-Impermeable Endoprosthesis, which recently received FDA premarket approval. This approval marks a significant milestone in Merit’s strategic initiative started in 2010, aiming to transition into higher-value medical devices. The launch of the Wrapsody CIE is seen as the beginning of further developments, as Merit has made both organic and inorganic investments to broaden its therapeutic platform and strengthen its market position, especially in dialysis. The company looks forward to leveraging its strategic foundation for future growth.
More about Merit Medical Systems
Merit Medical Systems is a company in the MedTech industry, primarily focused on developing high-value, therapeutic medical devices. Their products serve key markets and strengthen relationships with physician customers, particularly in the dialysis market.
YTD Price Performance: 10.16%
Average Trading Volume: 468,715
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.1B
For a thorough assessment of MMSI stock, go to TipRanks’ Stock Analysis page.
